ReviewCurrent cardiology reports2020
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).
Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management.BMC cardiovascular disorders · 2026Pooled it
- Precision Lipid Management in the Era of Biotechnology and Artificial Intelligence: From Gene Editing to Smart Drug Delivery.Therapeutic innovation & regulatory science · 2026Review
- Review: natural compounds as PCSK9 inhibitors for antiviral therapy.Archives of microbiology · 2026Review
- The effect of PCSK9 inhibitors on cardiovascular outcomes in diabetic patients: a narrative review.Frontiers in pharmacology · 2026Review
- Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics.Advances in experimental medicine and biology · 2026Review
- Autophagy as a Proposed Regulatory Interface in the Gut Microbiota-Cardiovascular Axis.Journal of inflammation research · 2026Review
- Risk Factor Assessments and Lipid Management Patterns in Hospitalised Patients in Malaysia: The Atherosclerotic Cardiovascular Disease Study.The Malaysian journal of medical sciences : MJMS · 2025Article
- Systemic evaluation of inclisiran on the risk of new-onset diabetes and hyperglycemia compared to evolocumab and atorvastatin.Frontiers in pharmacology · 2025Article
- The Impact of COVID-19 on RNA Therapeutics: A Surge in Lipid Nanoparticles and Alternative Delivery Systems.Pharmaceutics · 2024Review
- Investigating the potential of catheter-assisted pulsed focused ultrasound ablation for atherosclerotic plaques.Medical physics · 2024Article
- Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease?Cardiology and therapy · 2024Review
- [Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations].Innere Medizin (Heidelberg, Germany) · 2023Review
- Inclisiran-Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9.Pharmaceutics · 2023Review
- PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection.Current cardiology reports · 2022Review
- Multivalent Display of ApoAI Peptides on the Surface of Tobacco Mosaic Virus Nanotubes Improves Cholesterol Efflux.Bioconjugate chemistry · 2022Article
- Potential of Phage Display Antibody Technology for Cardiovascular Disease Immunotherapy.Journal of cardiovascular translational research · 2022Review
- Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
- Function of the endolysosomal network in cholesterol homeostasis and metabolic-associated fatty liver disease (MAFLD).Molecular metabolism · 2021Review
- Utilization of the human gamma-satellite insulator for the enhancement of anti-PCSK9 monoclonal antibody expression in Chinese hamster ovary cells.Molecular biology reports · 2021Article
- Inflammation and Cardiovascular Disease: The Future.European cardiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe aim of low-density lipoprotein-cholesterol (LDL-C) lowering therapies is to safely achieve a consistent and long-term reduction in exposure of the vasculature to atherogenic lipoproteins in order to reduce the risk of atherosclerotic cardiovascular (CV) disease and the associated CV events, such as myocardial infarctions and ischemic strokes. This review summarizes the concept and clinical development of a novel molecular approach to efficiently lower LDL-C, a synthetic small interfering ribonucleic acid (siRNA)-inclisiran-directed against proprotein convertase subtilisin-kexin type 9 (PCSK9). RECENT
findingsThe understanding of genes regulating atherogenic lipoproteins and their causal role in the development of atherosclerotic CV disease has substantially advanced over the past years. This has opened the possibility for development of molecular therapies targeting these atherogenic lipoproteins, in particular by RNA-targeted treatment approaches. The most advanced clinical development program is the siRNA-treatment targeting PCSK9 (inclisiran), involving more than 4000 patients in clinical studies. Phase 1 and 2 studies have identified the dose of 300 mg inclisiran for efficient LDL-C lowering. Most recently, three phase 3 studies demonstrated that a regimen of inclisiran every 6 months was feasible and reduced LDL-C by approximately 50% in patients at high or very high CV risk or with familial hypercholesterolemia. Adverse events were similar in the inclisiran and the placebo groups, except for more frequent transient injection site reactions with inclisiran than with placebo. siRNA therapy targeting PCSK9 (inclisiran) applied twice a year efficiently reduced LDL-C by approximately 50% and was safe in recent phase 3 studies. The effects of this treatment on CV outcome are currently further assessed in a large ongoing CV outcome trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.